Open and enrolling here at IU Simon Comprehensive Cancer Center

Congrats to all the new board certified Oncologists who found out this week they passed!😊 This week we had world expert Dr. Pat Loehrer IU Simon Comprehensive Cancer Center talk to us about Thymomas & Thymic Carcinomas. Next week he shares regimens for more advanced disease & advice for trainees

Outstanding work from our liver transplant surgery team in 2024! 215 patient lives impacted! Top 5 in the country! Congrats!!

Very excited to see this in print! Such promising outcomes for immune cold #sarcomas with Botensilimab Plus Balstilimab ascopubs.org/doi/10.1200/JC… Agenus CU Cancer Center

Tune in for 2 episodes with Stephen V Liu, MD on Small Cell Lung Cancer! We discuss 🔑 pearls on risk factors, diagnostic work-up, staging and tx of both locoregional and metastatic #SCLC, options for relapsed/refractory disease & advice for trainees.

We released a new episode this week on exciting data to look forward to at #ASCOGU25 - a roundup of the data will be released next week 🌟 & the following will be back with more Myeloma updates 🧬 podcasts.apple.com/us/podcast/two…

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor. Vimseltinib achieved a 40% ORR in #TGCT patients, significantly outperforming placebo in the MOTION trial. ⁦TGCT Support⁩ ⁦The Life Raft Group⁩ #sarcoma onclive.com/view/fda-appro…

You know #ASCO25 is < 3 months away! It’s never too early to start planning, especially if you are going to be taking your boards! Onc Board Review, w/ TwoOncDocs + Oncology Brothers: 📅 May 29: theWit Chicago ✅ Register: bit.ly/boards2025 #OncTwitter SignifyMD

🚨Calling all @asco #ASCO25 annual meeting attendees! Come join us in person for our annual #MedEd CoP event!! 🔔 Saturday May 31st 🔔 7:30-9:30 am 🔔 Room S103 ‼️Keynote speakers: TwoOncDocs and Oncology Brothers!! Can’t wait to see you there!! 🥰

Can’t wait to hear from TwoOncDocs and Oncology Brothers during this great session!! Samantha Armstrong Karine Tawagi MD Rami Manochakian MD, FASCO Cancer Education Kathy Walsh, MD, MAEd Sam Brondfield, MD, MAEd, FASCO IU Simon Comprehensive Cancer Center IU School of Medicine Indiana University Hematology/Oncology Fellowship

We are just 1 day away from our Clinicals to Exam board prep co-hosted with Oncology Brothers We will cover high yield tips on: 🌟 board prep 101 🌟 breast CA 🌟 NSCLC 🌟 CRC 🌟 testicular CA 🌟 prostate CA Looking forward to seeing you all in Chicago tomorrow to kick off #ASCO25

Oncology Board Prep (#ClinicalsToExam) today with TwoOncDocs! Then starting tomorrow, let’s take a dive into all the data coming at us from #ASCO25! #OncTwitter #MedTwitter

Thank you all who joined Clinicals to Exams & guest appearance w/ baby Cary A few high-yield mnemonics: 🌟 ribociclib - “ribs” close to ❤️- Qtc; abemaciclib - “abs” - diarrhea 🌟 tumor marker half-life: Hcg -3 letters, 1-3d; AFP -alpha - 5 letters 5-7d Ready for #ASCO25 day 1!

🤩 TwoOncDocs Oncology Brothers Happening NOW in S103 ‼️

Honored to have been a keynote speaker this morning as half of TwoOncDocs with Karine Tawagi MD along side Oncology Brothers #asco2025 #MedEd

Honored to be invited for the ASCO OncMedEdCoP Keynote this AM w/ Oncology Brothers! We discussed why, how, balance, topics, branding, research (podcast curriculum with The Fellow On Call to be presented at 1:15PM today), promotion, the changing landscape of med ed & digital ed #ASCO25

Our wonderful The Fellow On Call colleague Dr. Vivek Patel presenting final results from our multicenter randomized PODCAST-HOF trial And hot off the press today, publication in JCO: ascopubs.org/doi/pdfdirect/… #ASCO25

PFS benefit with anlotinib+doxo and anlotinib maintenance. Lower than expected ORR in doxo arm and almost impossible to believe equivalence in toxicity between the arms. Same question as doxo+trabectedin: what if sequential single agent were used? #ASCO25

#ATOMIC phase 3 trial: stage 3 CRC adjuvant Atezolizumab + FOLFOX vs FOLFOX For fellows ➡️where it fits in to current practice All pts need MMR testing! 10-15% localized CRC are dMMR 🌟 new SOC 10% improvement in 3yr DFS but also good results for neoadj IO #NICHE2 #ASCO25

This week we released 2025 updates on soft tissue #sarcoma with our local sarcoma expert Samantha Armstrong Which of the following is a preferred approved treatment since 2023 for unresectable desmoid tumors? Hem-Onc Fellows Network